lncRNA:mRNA expression profile in CD4+ T cells from patients with Graves' disease.
lncRNA:mRNA expression profile in CD4+ T cells from patients with Graves' disease.
复制标题
lncRNA：Graves 病患者 CD4 T 细胞中 mRNA 表达谱
DOI：
10.1530/ec-20-0373
复制
发表时间：
2020-12
影响因子：
2.9
通讯作者：
Wang S
中科院分区：
文献类型：
--
作者：
Yin Q;Jin Z;Zhou Y;Song D;Fu C;Huang F;Wang S
Graves病(GD)是一种影响甲状腺的常见自身免疫性疾病。作为一类新的基因表达调控因子，长非编码RNA(LncRNAs)在免疫功能以及自身免疫和自身免疫性疾病的发生发展中发挥着重要作用。本研究的目的是确定CD4+T细胞中的lncRNAs是GD的潜在生物标志物。应用lncRNA和mRNA微阵列技术检测GD患者外周血中与健康对照的CD4+T细胞中差异表达的cncRNA和mRNAs。用定量聚合酶链式反应(QPCR)验证结果，并用相关分析分析这些异常表达的lncRNAs与临床参数的关系。该芯片鉴定出与健康对照的CD4+T细胞相比，GD CD4+T细胞中存在164个lncRNA和93个mRNAs的差异表达(折叠式变化2.0和P<；0.05)。进一步分析一致显示，在初发GD患者中，HMlincRNA1474(P<；0.01)和Tons_00012608(P<；0.01)的表达受到抑制，而AK021954(P<；0.01)和AB075506(P<；0.01)的表达则上调。此外，在甲状腺功能正常的GD患者和缓解期的GD患者中，其表达水平也有所恢复。此外，这四种异常表达的LncRNAs与GD的临床参数相关。AK021954、AB075506、HMlincRNA1474的ROC曲线下面积分别为0.8046、0.7579、0.8115。本研究表明差异表达的lncRNAs与GD相关，可能成为GD的新的生物标志物和治疗的潜在靶点。
Graves’ disease (GD) is a common autoimmune disease that affects the thyroid gland. As a new class of modulators of gene expression, long noncoding RNAs (lncRNAs) have been reported to play a vital role in immune functions and in the development of autoimmunity and autoimmune disease. The aim of this study is to identify lncRNAs in CD4+ T cells as potential biomarkers of GD. lncRNA and mRNA microarrays were performed to identify differentially expressed lncRNAs and mRNAs in GD CD4+ T cells compared with healthy control CD4+ T cells. Quantitative PCR (qPCR) was used to validate the results, and correlation analysis was used to analyze the relationship between these aberrantly expressed lncRNAs and clinical parameters. The microarray identified 164 lncRNAs and 93 mRNAs in GD CD4+ T cells differentially expressed compared to healthy control CD4+ T cells (fold change >2.0 and a P < 0.05). Further analysis consistently showed that the expression of HMlincRNA1474 (P < 0.01) and TCONS_00012608 (P < 0.01) was suppressed, while the expression of AK021954 (P < 0.01) and AB075506 (P < 0.01) was upregulated from initial GD patients. In addition, their expression levels were recovered in euthyroid GD patients and GD patients in remission. Moreover, these four aberrantly expressed lncRNAs were correlated with GD clinical parameters. Moreover, the areas under the ROC curve were 0.8046, 0.7579, 0.8115 for AK021954, AB075506, HMlincRNA1474, respectively. The present work revealed that differentially expressed lncRNAs were associated with GD, which might serve as novel biomarkers of GD and potential targets for GD treatment.